Wuhan Hiteck Biological Pharma Co Ltd (300683) — Cash Flow Quality Index
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Cash Flow Quality Index of 1.89x as of June 2022. Operating cash flow of CN¥21.11 Million exceeds net income of CN¥11.18 Million, indicating high earnings quality where cash backs reported profits. Explore cash efficiency ratio of Wuhan Hiteck Biological Pharma Co Ltd to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Wuhan Hiteck Biological Pharma Co Ltd Cash Flow Quality Index (2013–2021)
Historical Cash Flow Quality Index for Wuhan Hiteck Biological Pharma Co Ltd across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Wuhan Hiteck Biological Pharma Co Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Wuhan Hiteck Biological Pharma Co Ltd (2013–2021)
Year-by-year earnings quality comparison for Wuhan Hiteck Biological Pharma Co Ltd. For live market cap and the full company financial profile, see market value of Wuhan Hiteck Biological Pharma Co Ltd.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 0.40x | CN¥12.09 Million | CN¥30.01 Million | ▼ -60.9% |
| 2019 | 1.03x | CN¥63.03 Million | CN¥61.19 Million | ▲ +28.3% |
| 2018 | 0.80x | CN¥73.42 Million | CN¥91.46 Million | ▲ +36.4% |
| 2017 | 0.59x | CN¥83.08 Million | CN¥141.20 Million | ▼ -35.9% |
| 2016 | 0.92x | CN¥143.86 Million | CN¥156.74 Million | ▼ -52.2% |
| 2015 | 1.92x | CN¥159.89 Million | CN¥83.23 Million | ▲ +54.6% |
| 2014 | 1.24x | CN¥135.40 Million | CN¥108.97 Million | ▲ +25.6% |
| 2013 | 0.99x | CN¥76.82 Million | CN¥77.65 Million | — |